A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SKB565 for Injection in Participants With Advanced Solid Tumors
Latest Information Update: 05 May 2026
At a glance
- Drugs SKB 565 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Kelun-Biotech Biopharmaceutical
Most Recent Events
- 05 May 2026 New trial record